Why the study?
The clinical benefit of new short-acting beta-blockers in critically ill patients is not sufficiently known or fully appreciated.
This review highlights the potential clinical utility of landiolol, an ultra-short-acting beta-blocker, across various critical cardiovascular conditions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tomáš Janota (2020) conducted a review in Tachycardia, tachyarrhythmias, heart failure, shock. Landiolol was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: